Reaction

Hypopituitarism reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,720 reports · 53 co-occurring drugs

As of the last recalculation, Hypopituitarism appears in 1,720 FAERS reports alongside 53 co-occurring drug terms. The strongest observed disproportionality signal is IPILIMUMAB (PRR 160.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ipilimumab	430	160.4	162.0
Nivolumab	465	79.4	79.8
Pembrolizumab	226	29.8	29.8
Atezolizumab	83	27.1	27.2
Thiotepa	21	26.9	27.0
Durvalumab	42	25.6	25.6
Pemetrexed	35	20.1	20.2
Fluticasone Furoate	18	18.2	18.2
Anti-Itch	95	18.1	18.1
Anti-Pruritic	95	18.1	18.1
Antipruritic (Anti-Itch)	95	18.1	18.1
Cool Relief Gel With Aloe	95	18.1	18.1
Drs. Hydrocortisone	95	18.1	18.1
Hydrocortisone Continuous Spray	95	18.1	18.1
Hydrocortisone Spray	95	18.1	18.1
Anti-Itch Cream	95	18.1	18.1
Hydrocortisone Lotion	95	18.1	18.1
Hydrocortisone Cream 1%	95	18.1	18.1
Hydrocortisone Cream 1/2%	95	18.1	18.1
Hydrocortisone 1%	95	18.1	18.1
Hydrocortisone Cream	95	18.0	18.0
Hydrocortisone Acetate	100	17.6	17.6
Carboplatin	164	17.2	17.2
Pemetrexed Disodium	51	16.7	16.7
Hydrocortisone	108	15.6	15.6
Paclitaxel	108	14.0	14.0
Paclitaxel (Aibumin-Bound)	89	13.8	13.8
Febuxostat Tablets 40 Mg	11	13.2	13.2
Febuxostat Tablets 80 Mg	11	13.2	13.2
Fexofenadine Hcl	10	13.2	13.2
Somatropin	68	11.6	11.6
Encorafenib	9	11.1	11.1
Epoprostenol	11	10.2	10.2
Lenvatinib	27	10.1	10.1
Axitinib	15	9.4	9.4
Magnesium Oxide	31	9.1	9.1
Febuxostat	11	8.0	8.0
Fondaparinux Sodium	5	7.5	7.5
Bicalutamide	9	7.2	7.2
Pitavastatin Calcium	6	7.1	7.1
Granisetron Hydrochloride	6	7.0	7.0
Entecavir	6	6.2	6.2
Fosaprepitant Dimeglumine	7	6.2	6.2
Cabozantinib	24	6.1	6.1
Cisplatin	38	6.0	6.0
Bleomycin Sulfate	5	5.9	5.9
Tolvaptan	7	5.8	5.9
Temozolomide	10	5.8	5.8
Bevacizumab	55	5.5	5.5
Suvorexant	5	4.7	4.7
Methadone Hydrochloride	4	4.5	4.5
Vigabatrin	4	3.3	3.3
Emicizumab	3	2.9	2.9

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.